Marvin Shepherd
Marv Shepherd earned his B.S. in biology (1969) from Michigan Technological University, a B.S. in pharmacy from Ferris State University (1975), M.S. from the University of Rhode Island (1978) and Ph.D. from Purdue University (1980). In 1969, he received his commission in the U.S. Army and served with the 10th Special Forces Group (Green Berets). He was a professor at the College of Pharmacy University of Texas at Austin for 33 years; he served as the Director of the Center for Pharmacoeconomic Studies and Chairman of the Pharmacy Administration Division. He is currently the President of the Partnership for Safe Medicines an organization dedicated to fighting counterfeit medications, drug diversion and informing health professionals and consumers about fake, substandard and diverted drug products.
He has conducted research on drug importation, drug counterfeiting, drug diversion and pharmaceutical cargo theft for over 20 years. His research and expertise on drug diversion, drug importation, drug counterfeiting and pharmaceutical cargo theft has been featured on CNN News, NPR Radio: First Edition, Newsweek, Wall Street Journal, Money Magazine, Time Magazine, Prevention Magazine, US News and World Report, New York Times, USA Today, Washington Post, plus many other national newspapers, magazines and television and radio news broadcasts. He has testified before U.S. Congress on drug importation, prescription drug diversion and counterfeit drugs.
He has conducted research on drug importation, drug counterfeiting, drug diversion and pharmaceutical cargo theft for over 20 years. His research and expertise on drug diversion, drug importation, drug counterfeiting and pharmaceutical cargo theft has been featured on CNN News, NPR Radio: First Edition, Newsweek, Wall Street Journal, Money Magazine, Time Magazine, Prevention Magazine, US News and World Report, New York Times, USA Today, Washington Post, plus many other national newspapers, magazines and television and radio news broadcasts. He has testified before U.S. Congress on drug importation, prescription drug diversion and counterfeit drugs.
less
Interests
Uploads
Papers by Marvin Shepherd
AUTHOR
Marv Shepherd, Ph.D. Professor Emeritus, College of Pharmacy, University of Texas at Austin; Board Member Partnership for Safe Medicines.
ABSTRACT
Within recent months, the U.S. has opened up the possibility for Americans to import prescription pharmaceuticals from Canada. The U.S. FDA is now accepting proposals for both personal and commercial drug importation from Canada. Importers can be individuals, wholesalers, pharmacies, and governments. This research examines the impact U.S. drug importation will have on the Canadian prescription drug supply. Using the total number of prescriptions dispensed in 2018 for Canada and the U.S., models were developed to estimate the number of days before the Canadian drug supply would be exhausted. The model included variations in the demand for prescriptions from the U.S. and included a safety stock of 10%. Models were developed for both total drugs and for just brand name pharmaceuticals. The study shows that U.S. commercial importation will enhance the risk to the Canadian health care system. Serious drug shortages are predicted unless Canada puts a halt to exporting drugs to the U.S.
AUTHOR
Marv Shepherd, Ph.D. Professor Emeritus, College of Pharmacy, University of Texas at Austin; Board Member Partnership for Safe Medicines.
ABSTRACT
Within recent months, the U.S. has opened up the possibility for Americans to import prescription pharmaceuticals from Canada. The U.S. FDA is now accepting proposals for both personal and commercial drug importation from Canada. Importers can be individuals, wholesalers, pharmacies, and governments. This research examines the impact U.S. drug importation will have on the Canadian prescription drug supply. Using the total number of prescriptions dispensed in 2018 for Canada and the U.S., models were developed to estimate the number of days before the Canadian drug supply would be exhausted. The model included variations in the demand for prescriptions from the U.S. and included a safety stock of 10%. Models were developed for both total drugs and for just brand name pharmaceuticals. The study shows that U.S. commercial importation will enhance the risk to the Canadian health care system. Serious drug shortages are predicted unless Canada puts a halt to exporting drugs to the U.S.